Mirabegron: a Beta-3 agonist for overactive bladder.
Mirabegron: a Beta-3 agonist for overactive bladder.
复制标题
DOI：
10.4140/tcp.n.2014.823
复制
发表时间：
2014-12
期刊：
影响因子：
--
通讯作者：
Pitlick JM
中科院分区：
文献类型：
--
作者：
Bragg R;Hebel D;Vouri SM;Pitlick JM
综述关于米拉贝隆治疗膀胱过度活动症（OAB）的有效性和安全性的文献。在2013年12月31日之前，使用MEDLINE（PubMed），使用术语"米拉贝隆"和"随机对照试验"进行文献检索。纳入了所有评估米拉贝隆的已发表、双盲、随机对照试验。如果mirabegron用作单药治疗，并且如果主要结局分析药物疗效，则对文章进行审查并纳入。米拉贝隆治疗OAB的疗效已在选定的5项随机、安慰剂对照试验中得到证实。这些试验中的大多数持续12周，并将不同剂量的米拉贝隆与安慰剂和/或托特罗定缓释剂（ER）进行了比较。试验的主要疗效结局包括每24小时平均排尿次数和每24小时平均失禁发作次数。纳入的试验显示，与安慰剂相比，不同剂量的米拉贝隆的两种疗效结局均出现统计学显著性降低。根据回顾的试验，Mirabegron可有效减少每24小时排尿和失禁发作的平均次数，并改善其他次要结局，如OAB症状和生活质量指标。米拉贝隆常见的药物不良反应包括：高血压、鼻咽炎、尿路感染、头痛、便秘、上呼吸道感染、关节痛、腹泻、心动过速、腹痛和疲劳。鉴于目前可用的疗效和安全性数据，米拉贝隆是OAB患者抗毒蕈碱药物的合理替代品。需要进一步研究以确定米拉贝隆在各种人口统计学中对OAB的效用。
To review the literature regarding the efficacy and safety of mirabegron for the treatment of overactive bladder (OAB). A literature search was performed using MEDLINE (PubMed) prior to 12/31/2013 using the terms “mirabegron” and “randomized-controlled trial.” All published, double-blind, randomized controlled trials assessing mirabegron were included. Articles were reviewed and included if mirabegron was used as monotherapy and if the primary outcome analyzed drug efficacy. The efficacy of mirabegron for the treatment of OAB has been demonstrated in the selected five randomized, placebo-controlled trials. The majority of these trials lasted 12 weeks in duration and compared various doses of mirabegron to placebo and/or tolterodine extended release (ER). Primary efficacy outcomes for the trials included mean number of micturitions per 24 hours and mean number of incontinence episodes per 24 hours. Included trials showed statistically significant reductions in both efficacy outcomes for various doses of mirabegron when compared to placebo. Based on the trials reviewed, mirabegron has been efficacious in reducing mean number of micturitions and incontinence episodes per 24 hours, as well as improved other secondary outcomes like OAB symptoms and quality of life measures. Common adverse drug events seen with mirabegron include: hypertension, nasopharyngitis, urinary tract infections, headache, constipation, upper respiratory tract infection, arthralgia, diarrhea, tachycardia, abdominal pain, and fatigue. Given the efficacy and safety data currently available, mirabegron represents a reasonable alternative to antimuscarinics for patients with OAB.Future studies are needed to determine the utility of mirabegron for OAB in a variety of demographics.